Pulmonx Corp (LUNG) Stock Price & Analysis

Pulmonx Corp (LUNG) fell 2.21% to USD 2.21 as of September 8, 2026 at 05:05 UTC, according to Nexqual real-time market data.

LUNG last closed at USD 2.21; the session ranged USD 2.19–2.3 on volume of 220,377 shares. Market capitalization is —, with a 52-week range of USD 1.13–2.89 (NMS). Source: Nexqual, September 8, 2026 at 05:05 UTC.

Key Statistics (as of September 8, 2026 at 05:05 UTC)

Technical Analysis (LUNG)

Nexqual's technical model rates LUNG "BUY" based on 4 bullish and 2 bearish signals across 128 daily candles, as of September 8, 2026 at 05:05 UTC.

From Pulmonx Corp's Latest SEC 10-K Filing (filed 2026-03-10)

Key Strengths & Strategy (as disclosed to the SEC)

• The AeriSeal System has received a "Breakthrough Device" designation by the FDA and a Certificate of Conformity ("CE Mark") in Europe.
• The AeriSeal System is not approved by the FDA or approved for commercial sale in the United States.
• Chartis Pulmonary Assessment System The Chartis System is a proprietary balloon catheter and console system with flow and pressure sensors designed to assess the presence of collateral ventilation and has been validated in multiple randomized controlled clinical trials to predict likely responders to Zephyr Valve treatment.
• Commercial payors such as Aetna, Humana, and many of the largest Blue Cross Blue Shield plans including Anthem, Health Care Service Corporation, BCBS Michigan, and Highmark have all issued positive coverage policies for the Zephyr Valve, and United Healthcare no longer considers the procedure unproven or experimental.

Partnerships

• We continue to develop our relationships with credible third parties, such as our partnership with the American College of Chest Physicians and Medscape, on continuing medical education-accredited training and with the American Lung Association and the COPD Foundation on patient and physician education.
• Cross-Licensing Agreement with Spiration/Olympus In January 2005, Emphasys Medical ("Emphasys"), a company we later acquired, entered into a cross-license agreement ("Spiration Cross-License") with Spiration, Inc. ("Spiration") (later acquired by Olympus Medical Systems Corp.).

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 05:05 UTC. This page is informational and not investment advice.